Skip to content

CYP26A1 is involved in neuropathic pain through RXRβ-mediated neuronal excitability and neuroinflammation in the DRG.

Nov 2026 · European Journal of Pharmacology · pp. 179550 · 0 citations · 61 references
Medicine

Abstract

Neuropathic pain remains a challenging clinical problem with limited therapeutic options. As the key enzyme responsible for catabolizing all-trans-retinoic acid (RA), CYP26A1 is crucial for maintaining RA homeostasis, yet its role in neuropathic pain remains unclear. In this study, we report that spinal nerve ligation (SNL) increased CYP26A1 expression in dorsal root ganglion (DRG) neurons. Both local DRG injection of CYP26A1-targeting siRNA and talarozole, a specific CYP26A1 inhibitor, significantly attenuated SNL-induced mechanical allodynia and thermal hyperalgesia. At the molecular level, CYP26A1 inhibition shifted the local cytokine balance, suppressing the pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 while upregulating the anti-inflammatory cytokine IL-10 within the DRG. Electrophysiological recordings further revealed that talarozole treatment reduced the hyperexcitability of DRG neurons in SNL mice. Moreover, SNL induced dysregulation of RA receptor expression in DRG neurons, characterized by increased RA receptor alpha (RARα) and decreased retinoid X receptor beta (RXRβ). In addition, DRG-specific overexpression of RXRβ not only alleviated mechanical allodynia and thermal hyperalgesia but also inhibited pro-inflammatory cytokine expression and reduced neuronal hyperexcitability in SNL mice. Collectively, our findings reveal that inhibiting CYP26A1 or restoring RXRβ expression in the DRG can alleviate neuropathic pain by reducing the neuroinflammatory response and suppressing neuronal hyperexcitability. Thus, targeting the CYP26A1/RXRβ signaling may represent a novel therapeutic strategy for neuropathic pain.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.